Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-27 receptor subunit alpha (IL-27Rα or WSX-1) is a transmembrane cytokine receptor that, together with the common co-receptor gp130, forms the functional receptor complex for interleukin-27 (IL-27). When IL-27 binds this receptor complex, it activates the JAK/STAT signaling pathway, especially STAT1 and STAT3, leading to modulation of T cell-mediated inflammation and regulation of immune homeostasis. IL-27Rα is crucial in limiting excessive immune responses and promoting immune tolerance, with important roles in infection, autoimmunity, and antitumor immunity. Growing structural insight into the receptor complex is facilitating the development of therapeutic strategies aiming to selectively modulate IL-27 signaling in oncology and inflammatory diseases.
Drugs/antibodies targeting IL-27Rα would act by modulating or blocking IL-27 signaling, altering STAT1/STAT3-mediated transcription, suppressing or enhancing T cell responses, and impacting cytokine milieu in the tissue microenvironment.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-27 receptor subunit alpha (IL-27Rα).